Herbesan Desmodium Bien-être du foie
Food supplement declared in France, declaration No 2017-7-697
Herbesan Desmodium Bien-être du foie, from LABORATOIRES SUPER DIET, is a food supplement declared in France. Status: withdrawn from the market on 26 June 2026. Main ingredients: Raphanus raphanistrum 7627.5 mg per day, Desmodium adscendens 300 mg per day, Cynara scolymus 255 mg per day, Rosmarinus officinalis 50 mg per day, Cynara scolymus 45 mg per day. None of the rules we check flags an issue with its declared composition.
- Brand
- Herbesan
- Food business operator placing the product on the market
- LABORATOIRES SUPER DIET
- Status
- Withdrawn from the market on 26 June 2026
- Form
- Ampoule
- Daily dose
- 1 ampoule par jour
- Directions for use
- pure ou diluée dans un demi-verre d'eau.
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Pregnant women, Taking thyroid medication
- Objectives stated by the manufacturer (these are not authorised claims)
- Detox / Drainage
Declaration 282425, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Raphanus raphanistrum subsp. sativus (L.) Domin | Racine | Autre extrait fluide | 7627.5 mg |
| Desmodium adscendens (Sw.) DC. | Feuille | Extrait fluide aqueux | 300 mg |
| Cynara scolymus L. | Feuille | Extrait sec aqueux | 255 mg |
| Rosmarinus officinalis L. | Feuille | Extrait fluide aqueux | 50 mg |
| Cynara scolymus L. | Feuille | Extrait fluide aqueux | 45 mg |
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Label warnings
Autre consommation déconseillée : Ne convient pas en cas d'allergie à l'artichaut ou aux Astéracées. Déconseillé en cas de calculs biliaires. Déconseillé en cas d’hypothyroïdie ou de traitement de la thyroïde, consultez préalablement un professionnel de santé.Réservé à l'adulte. Si vous suivez un traitement, demandez l'avis de votre médecin.
Regulatory points
- Information
Withdrawn from the market on 26 June 2026, according to Compl'Alim.
Source: Compl'Alim, food supplement declarations (France).
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Rosmarinus officinalis L.
Read the warning, when it applies and the studies cited
ROSEMARY – ROSMARINUS OFFICINALIS Oral
Route of administration: Oral (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Health Canada monograph dated 29 May 2026
ROSEMARY - ROSMARINUS OFFICINALIS Topical
Route of administration: Topical (ESCOP 2003)
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000).
Sources cited by Health Canada (4)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Gardner Z, McGuffin M, editors. American Herbal Products Association’s Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have large open wounds, skin lesions, feverish conditions, acute inflammation, severe circulatory disorders or hypertension (ESCOP 2003).
Sources cited by Health Canada (1)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Barnes et al. 2007; ESCOP 2003).
Sources cited by Health Canada (2)
- Barnes J, Anderson LA, Philipson JD. Herbal Medicines, 3rd edition. London (UK): The Pharmaceutical Press; 2007.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Brand : Herbesan
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Herbesan Desmodium Bien-être du foie: composition and regulation”, https://compoatlas.com/en/supplements/products/282425-herbesan-desmodium-bien-etre-du-foie, updated 15 November 2026.